AI assistant
ADHERIUM LIMITED — Capital/Financing Update 2018
Sep 3, 2018
64305_rns_2018-09-03_2820d073-f4dc-4973-b6f9-3e5336a33f33.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [211 x 51] intentionally omitted <==
Expiry of Unlisted Options
San Mateo, CA – September 4, 2018: Adherium Ltd (ASX: ADR, the Company or Adherium) advises that the following unlisted options in the Company have lapsed:
| Number ofUnlisted Options | To Acquire | Exercise Price | Expiry Date |
|---|---|---|---|
| 1,400,000 | Fully paid ordinary sharesin Adherium (ASX:ADR) | $0.665 | 3 September 2018(threeyears after date ofcorporate advisoryagreement) |
Rob Turnbull Company Secretary
About Adherium
Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with over 130,000 sold globally. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of connected medical devices for respiratory medications. The devices and accompanying technology address sub-optimal medication use and strive to improve health outcomes in chronic disease. Adherium is headquartered in the USA, and operates globally from bases in the USA, Europe and Australasia. Learn more at www.adherium.com